In the latest trading session, 5.83 million Humacyte Inc (NASDAQ:HUMA) shares changed hands as the company’s beta touched 1.36. With the company’s most recent per share price at $4.37 changed hands at -$0.27 or -5.82% at last look, the market valuation stands at $754.06M. HUMA’s current price is a discount, trading about -128.15% off its 52-week high of $9.97. The share price had its 52-week low at $2.48, which suggests the last value was 43.25% up since then. When we look at Humacyte Inc’s average trading volume, we note the 10-day average is 10.12 million shares, with the 3-month average coming to 4.25 million.
Analysts gave the Humacyte Inc (HUMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HUMA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Humacyte Inc’s EPS for the current quarter is expected to be -0.25.
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA was in red as seen in intraday trades today. With action 0.69%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 53.88%, with the 5-day performance at 0.69% in the green. However, in the 30-day time frame, Humacyte Inc (NASDAQ:HUMA) is -0.23% down. Looking at the short shares, we see there were 20.33 million shares sold at short interest cover period of 6.37 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 45.38% from its recent market value. According to analyst projections, HUMA’s forecast low is 6 with 10 as the target high. To hit the forecast high, the stock’s price needs a -128.83% plunge from its current level, while the stock would need to soar -37.3% for it to hit the projected low.
Humacyte Inc (HUMA) estimates and forecasts
Data shows that the Humacyte Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -11.36% over the past 6 months, a -18.69% in annual growth rate that is considerably lower than the industry average of 17.20%.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 214.29k. 4 analysts are of the opinion that Humacyte Inc’s revenue for the current quarter will be 2.58M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2024 estimates are for Humacyte Inc earnings to decrease by -26.44%.
HUMA Dividends
Humacyte Inc is expected to release its next quarterly earnings report in January.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 26.87% of Humacyte Inc shares while 30.01% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 41.04%. There are 30.01% institutions holding the Humacyte Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 6.5961% of the shares, roughly 7.14 million HUMA shares worth $34.27 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 2.84 shares estimated at $12.29 million under it, the former controlled 2.26% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.06% of the shares, roughly 2.59 shares worth around $11.23 million.
